Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer

Official Title

A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer

Summary:

This randomized phase II trial studies how well cabozantinib and nivolumab work in treating patients with endometrial that has come back or spread to other places in the body. Cabozantinib may stop the growth of tumour cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumour cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.

Trial Description

Primary Outcome:

  • Progression free survival (PFS)
Secondary Outcome:
  • Overall response rate (ORR)
  • Overall survival (OS)
  • Incidence of adverse events
  • PD-L1 expression, CD3, CD4 and CD8 analysis
PRIMARY OBJECTIVES:
I. To evaluate the clinical anti-tumour activity of XL184 (cabozantinib) and nivolumab based on progression free survival (PFS) in patients with advanced, recurrent or metastatic endometrial cancer previously treated with at least one line of platinum-based chemotherapy compared to patients receiving nivolumab alone. SECONDARY OBJECTIVES:
I. To evaluate the efficacy of XL184 and nivolumab in terms of overall response rate (ORR) compared to nivolumab alone. II. To evaluate overall survival (OS) of patients receiving XL184 and nivolumab compared to patients receiving nivolumab alone. III. To evaluate the safety of combination treatment using XL184 and nivolumab in patients with advanced, recurrent metastatic endometrial cancer. IV. To evaluate correlation between PD-L1 expression, CD3, CD4 and CD8 infiltrates and outcome (PFS, ORR, OS). V. To compare PD-L1 expression, CD3, CD4 and CD8 infiltrates in the primary tumour (archival tissue) and in the tissue from baseline biopsy. VI. To assess activity (PFS, ORR and OS) of nivolumab alone or in combination with XL184 according to microsatellite instability (MSI)/mismatched repair (MMR) status. TERTIARY OBJECTIVES:
I. To assess activity (PFS, ORR and OS) of XL184 and nivolumab in patients progressed after previous exposure to anti PD-1, PD-L1 or PD-L2 agents or crossed-over from single agent nivolumab, and in patients with diagnosis of carcinosarcoma. II. To compare microsatellite (MS) and MMR status, in the primary tumour (archival tissue) and in the tissue from baseline biopsy. III. To assess the genomic and immune-markers landscape at baseline on tumour tissue and changes in immune landscape in peripheral blood during treatment and correlate with outcome. OUTLINE:

Patients are randomized to 1 of 2 arms. Arm A: Patients receive cabozantinib orally (PO) once daily (QD) on days 1-28 and nivolumab intravenously (IV) over 60 minutes on days 1 and 15, then on day 1 beginning course 5. Arm B: Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30-37 days, then every 12 weeks.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society